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To determine whether live-attenuated feline immunodeficiency virus (FIV) proviral DNA will induce protective immunity, a
plasmid clone constructed with a FIV provirus containing a deletion in the viral accessory gene vif (FIV-pPPR-Dvif) was
inoculated as proviral DNA into four cats by the intramuscular route. After 43 weeks, these cats were boosted with the same
proviral plasmid. Analysis of peripheral blood mononuclear cells at several time points after the primary and booster
inoculations revealed no detectable virus or proviral DNA. At 6 weeks after the booster, immunized cats and additional naive
control cats were challenged with a cell-free preparation of the infectious biological isolate FIV-PPR by the intraperitoneal
route. Virus was detected after challenge in unvaccinated control cats but not in any of the FIV-pPPR-Dvif-immunized cats.
Both FIV Gag- and Env-specific cytotoxic T lymphocyte (CTL) activities were detected in peripheral blood cells of control cats
after challenge infection, whereas only one of four cats immunized with FIV-pPPR-Dvif DNA exhibited a measurable CTL
response to Env following challenge. Although anti-Gag antibodies were not detected after both proviral DNA inoculation and
challenge, anti-Env antibodies were found in FIV-pPPR-Dvif-immunized cats after vaccination as well as after challenge.
These findings indicate that inoculation with FIV-pPPR-Dvif proviral DNA induced resistance to challenge with infectious FIV
and that a vif deletion mutant may provide a relatively safe attenuated lentiviral vaccine. © 2000 Academic Press
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1INTRODUCTION
Feline immunodeficiency virus (FIV) is a lentivirus that
causes progressive immunodeficiency syndrome in cats
that is characterized by CD4 T cell depletion. Thus, this
animal model is valuable for investigating human immu-
nodeficiency virus (HIV) infection in humans (Pedersen et
al., 1987; Siebelink et al., 1990; Willett et al., 1991). Ad-
antages of the FIV animal model include a genome
rganization and cell tropism similar to that of HIV and a
linical course and disease pathogenesis similar to that
f AIDS in humans (Beebe et al., 1994; Brown et al., 1991;
ean et al., 1996; Diehl et al., 1995; English et al., 1993;
albott et al., 1989; Willet et al., 1997; Woo et al., 1997;
amamoto et al., 1988). In addition, the FIV model system
rovides a practical, economical, and safe alternative to
he use of non-human primates in HIV research and the
evelopment of vaccines and therapies against AIDS.
Much of the work using the FIV model for vaccine
evelopment has focused on immunization with whole
nactivated-virus- or fixed-virus-infected cells. The first
1n
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67ffective FIV vaccine of this type used killed FIV-Peta-
uma-infected cells or inactivated whole FIV-Petaluma
irus and was shown to protect against challenge with
ow-dose homologous and some heterologous FIV iso-
ates (Yamamoto et al., 1991, 1993). However, subsequent
tudies have revealed that these vaccines cannot protect
gainst challenge with antigenically distinct FIV isolates
Bishop et al., 1996; Hosie et al., 1995; Johnson et al.,
994). In addition, one study using the fixed FIV-Peta-
uma-infected cell vaccine reported a breakthrough in
accine protection against homologous challenge when
nimals were monitored up to 50 weeks postchallenge
pc) (Bishop et al., 1996), and a second study using a
imilar fixed FIV-infected cell vaccine reported no pro-
ection from cell-free challenge at 1 year postvaccination
Matteucci et al., 1997). These results suggest that ster-
lizing immunity is not achieved and persistent latent
hallenge virus infections can occur despite vaccination
ith the inactivated FIV vaccines.
The most successful vaccines to date in the simian
mmunodeficiency virus (SIV) model have been live, at-
enuated viruses with deletions in viral accessory genes
Almond et al., 1995; Daniel et al., 1991; Wyand et al.,
996). Inoculation of adult and juvenile macaques with a
ef deletion mutant of SIV did not cause disease but
0042-6822/00 $35.00
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68 LOCKRIDGE ET AL.produced a persistent low-level infection and generated
anti-SIV antibodies. These immunized animals were pro-
tected from challenge with high doses of cell-free patho-
genic virus more than 2 years postvaccination (Almond
et al., 1995). However subsequent studies have reported
induction of AIDS after inoculation with an attenuated
SIV mutant with multiple deletions, including nef and vpr,
in neonatal macaques and in adult macaques after pro-
longed follow-up studies (Baba et al., 1995, 1999). There-
fore the attenuation and impairment of replication in-
duced by deletion of these genes was insufficient to
produce a safe nonpathogenic virus vaccine.
Inoculation of plasmid DNA transient expression vec-
tors directly into muscle tissue has been found to induce
long-lasting humoral and cellular immune responses to a
variety of pathogens, including influenza B virus, hepati-
tis B virus, and SIV; additionally, protection from chal-
lenge with heterologous antigens has been reported
(Chattergoon et al., 1997; Robinson et al., 1999). Several
reports demonstrated that inoculation of cloned proviral
DNA into animals resulted in virus expression and infec-
tion (Letvin et al., 1991; Portis et al., 1992; Rigby et al.,
997; Sparger et al., 1997; Willems et al., 1992). The
dvantages of DNA immunization over live-virus or inac-
ivated-virus preparations include the relative stability of
NA and ease of purification. Thus, it is feasible to
roduce large quantities of attenuated forms of virus as
lasmids containing proviral DNA in contrast to infec-
ious virus grown in cell cultures. Furthermore, problems
ssociated with inactivation steps and sequence
hanges resulting from passage of virus in cell culture
re not encountered when propagating and purifying
loned viral DNA plasmids.
In this study, we used injection of infectious proviral
NA as a mode for delivery of a vif deletion mutant of FIV.
e previously reported that inoculation of cats with wild-
ype (WT) FIV-pPPR proviral DNA produced an infection
etectable by both antiviral antibody and virus isolation
rom peripheral blood mononuclear cells (PBMC) and
iremia kinetics similar to that of inoculation with live
irus preparations (Sparger et al., 1997). The FIV-
PPRDvif proviral construct encodes a 375-bp deletion
ithin the vif (viral infectivity factor) gene and exhibits
ery low levels of virus replication compared to the WT
IV-pPPR in feline peripheral blood mononuclear cells
PBMC) and monocyte-derived macrophages in vitro
Lockridge et al., 1999), both target cell types for FIV
nfection in vivo (Beebe et al., 1994; Dean et al., 1996,
999; Dow et al., 1999; English et al., 1993). Lentivirus-
ncoded Vif functions at a late stage of the virus cycle
nd is critical for viral cell-free infectivity in vitro and in
ivo (Borman et al., 1995; Bouyac et al., 1997; Desrosiers
et al., 1998; Fouchier et al., 1996; Gabuzda et al., 1994;
Harmache et al., 1996; Inoshima et al., 1996; Sakai et al.,
1993; Shacklett and Luciw, 1994; Simon and Malim, 1996;
p
nTomonaga et al., 1992; vonSchwedler et al., 1993). Here
we demonstrate that inoculation of cats with FIV-
pPPRDvif proviral DNA protected cats against challenge
with the homologous FIV-PPR biological isolate. This
DNA vaccine induced low levels of anti-Env antibodies.
Protection was achieved without detectable viremia.
RESULTS AND DISCUSSION
Proviral DNA immunization and anti-viral immune
responses
Presence of the vif gene in genomes of all known
lentiviruses, except equine infectious anemia virus
(EIAV), suggests a critical role for this gene in lentiviral
infection and viral replication. Indeed, inoculation of
hosts with vif-deletion mutants of caprine arthritis en-
cephalitis virus (CAEV), SIV, and FIV have all resulted in
very low viral loads and minimal production of antiviral
antibodies (Desrosiers et al., 1998; Harmache et al.,
1996; Inoshima et al., 1996). In a previous report, we
described the vif-deletion mutant FIV-pPPRDvif derived
from WT infectious molecular clone FIV-pPPR (Phillips et
al., 1990; Sparger et al., 1994) and reported that replica-
tion of this mutant was severely restricted in cell-culture
systems of feline PBMC and monocyte-derived macro-
phages (Lockridge et al., 1999). To determine the in vivo
infectivity of FIV vif-mutant proviral DNA, we inoculated
cats with FIV-pPPRDvif proviral DNA and compared in-
fection kinetics to those of cats inoculated with either WT
FIV-pPPR or a biological FIV-PetalumaPBMC virus stock.
pecific pathogen free (SPF) cats were inoculated intra-
uscularly (im) with 600 mg of either FIV-pPPRDvif plas-
id DNA (n 5 4) or FIV-pPPR plasmid DNA (n 5 2) or
ntraperitoneally (ip) with 103 TCID50 of a FIV-Peta-
lumaPBMC virus stock (n 5 2) (Table 1). Two negative
ontrol cats were inoculated ip with uninfected tissue
ulture media. All of the FIV-pPPRDvif-inoculated cats
Nos. 073, 154, 212, and 213) and one of the WT pPPR-
noculated cats (No. 190) displayed a transient fever
tarting 3 h post inoculation (pi) that was resolved within
4 h, presumably due to residual endotoxin remaining in
he plasmid DNA preparation. No other adverse side
ffects were observed in cats as a result of im injection
f plasmid proviral DNA.
All cats receiving DNA inoculations remained clinically
ealthy and did not exhibit lymphadenopathy or notable
hanges in leukocyte or neutrophil counts compared to
he SPF control cats at any time following inoculation
data not shown). Lymphadenopathy and decreased
D4:CD8 T cell ratios were observed in both of the
IV-PetalumaPBMC-inoculated cats by 11 weeks pi as has
een previously described for this pathogenic FIV isolate
Barlough et al., 1991, 1993). However, neither WT FIV-
PPR- or FIV-pPPRDvif-inoculated cats exhibited a sig-
ificant decrease in CD4:CD8 T cell ratios when com-
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69VACCINATION OF CATS WITH vif-DELETED FIV PROVIRAL DNApared to age-matched, SPF control cats (data not
shown). Absence of CD4 T cell alterations has been
previously reported for the relatively nonpathogenic mo-
lecular clone FIV-pPPR (Dean et al., 1999; Sparger et al.,
1994).
We previously demonstrated that all cats inoculated im
with 100–300 mg of WT FIV-pPPR proviral DNA were virus
solation positive by 10 weeks pi (Sparger et al., 1997).
ats within the current study, inoculated im with 600 mg
of FIV-pPPRDvif proviral DNA, remained virus negative as
determined by semi-quantitative virus isolation from pe-
ripheral blood at various time points #43 weeks pi (Table
2). Virus was detected in both cats inoculated with FIV-
PetalumaPBMC virus and in one of two cats inoculated with
IV-pPPR plasmid DNA (No. 150) by 4 weeks pi. How-
ver, virus was not isolated from the second FIV-pPPR-
noculated cat (No. 190) and the four FIV-pPPRDvif-inoc-
lated cats or from the SPF negative control cats, for #43
T
Experimental Design for
Group
No. of
cats Inoculum
Fi
1 4 FIV-pPPRDvif
(FIV-Dvif)
60
2 2 FIV-pPPR-WT 60
3 2 FIV-Petaluma 10
4 2 Unimmunized me
5 2 SPF Control
a Cats infected with FIV-pPPR and FIV-Petaluma were euthanized (E
b ND designates not done.
TABLE 2
Detection of Virus in SPF Cats Inoculated
with FIV-pPPRDvif Proviral DNA
Cat
Virus
inoculum
Virus isolation weeks post-inoculation
2 4 8 12 16 27 43
073 FIV-Dvif 2a 2 2 2 2 2 2
154 FIV-Dvif 2 2 2 2 2 2 2
212 FIV-Dvif 2 2 2 2 2 2 2
213 FIV-Dvif 2 2 2 2 2 2 2
150 FIV-pPPR WT 2 104 106 105 105 Eb E
190 FIV-pPPR WT 2 2 2 2 2 E E
52 FIV-Petaluma 2 105 104 104 104 E E
191 FIV-Petaluma 2 104 103 104 104 E E
153 Unimmunized 2 2 2 2 2 2 2
211 Unimmunized 2 2 2 2 2 2 2
a PBMC cultures negative for FIV p24 are shown as 2; numbers
epresent lowest concentration of cells from which virus could be
solated by day 28 in culture.
b Cats infected with FIV-pPPR WT and FIV-Petaluma were euthanized
(E) 21 weeks pi.eeks pi. These results are consistent with those from
revious in vivo lentiviral vif-mutant inoculations in which
noculation of either FIVDvif virus in cats or SIVDvif virus
n monkeys did not induce viremia detectable by virus
solation from PBMC (Desrosiers et al., 1998; Inoshima et
l., 1996). Also similar to the SIVDvif virus inoculation
tudy, proviral DNA was not amplified by PCR from
BMC sampled at 8, 16, and 43 weeks after inoculation
r from popliteal lymph nodes harvested at 9 and 12
eeks pi (Table 3).
Cats were monitored for seroconversion by an ELISA
hat measures anti-FIV p24-Gag. Antibody responses
gainst FIV p24-Gag were detected by 8 weeks pi in both
IV-PetalumaPBMC virus-inoculated and FIV-pPPR-inocu-
lated cats and were sustained throughout the initial
phase of this study (Table 4). However, none of the
FIV-pPPRDvif-inoculated cats demonstrated detectable
antiviral antibody responses during the 43 weeks pi
when tested with a recombinant FIV p24 ELISA, with a
commercial FIV ELISA assay, or by Western blot. The
absence of detectable viremia and anti-p24-Gag anti-
body in FIV-pPPRDvif-inoculated cats suggests that FIV-
pPPRDvif replication was severely restricted or absent in
vivo. It is more likely that viral replication did occur but in
amounts below the detection limits of our assays or
replication may have occurred in cell subsets seques-
tered in tissues not tested by virus isolation.
Absence of detectable anti-p24-Gag antibody, when
assayed by standard serological assays, was previously
reported for monkeys inoculated with a SIVDvif virus
(Desrosiers et al., 1998) and in cats inoculated with
plasmid DNA containing a FIV provirus with an in-frame
deletion in pol (Hosie et al., 1998). However, an ultrasen-
sitive ELISA was capable of measuring anti-SIV antibod-
ies in all the SIVDvif-inoculated monkeys, and these
weak antibody responses persisted for more than a year.
To this end, a commercially available FIV ELISA assay, as
well as Western blot analysis, were used to re-test sera
RDvif Inoculation Study
ulation
k 0)
Second inoculation
(Week 43)
Challenge
(Week 49)
NA, i.m. 300 mg DNA, i.m. FIV-PPR, i.p.
NA, i.m. Ea E
0, i.p. E E
. NDb FIV-PPR, i.p.
ND media, i.p.
eks after first inoculation.ABLE 1
FIV-pPP
rst inoc
(Wee
0 mg D
0 mg D
3 TCID5
dia, i.p
NDfrom FIV-pPPRDvif-inoculated cats and were unable to
detect antiviral antibodies in these cats. To extend the
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70 LOCKRIDGE ET AL.analysis of this phenomenon, an FIV concanavalin A
(ConA) ELISA was used to detect antibody specific for
native FIV envelope proteins in cats inoculated with
FIV-pPPRDvif. Although none of the inoculated cats was
positive for anti-FIV Env antibody at 2 weeks after pro-
viral DNA inoculation (Fig. 1A), interestingly, all four FIV-
pPPRDvif-inoculated cats, as well as cats inoculated
with WT FIV-pPPR proviral DNA, were positive for anti-
Env antibody by 12 weeks pi with proviral DNA (Fig. 1B).
Although Env-specific antibody endpoint titers measured
for the four FIV-pPPRDvif-inoculated cats were lower
(four- to eightfold) than the positive control serum, their
titers were comparable to or greater than those found for
the WT FIV-pPPR-inoculated cats (data not shown). The
T
Detection of Proviral DNA in SPF Cat
Cat
Virus
inoculum
PBMC prov
0
073 FIV-Dvif 2
154 FIV-Dvif 2
212 FIV-Dvif 2
213 FIV-Dvif 2
150 FIV-pPPR WT 2
190 FIV-pPPR WT 2
152 FIV-Petaluma 2 N
191 FIV-Petaluma 2
153 Unimmunized 2
211 Unimmunized 2
TABLE 4
Detection of FIV p24 Antibody in SPF Cats Inoculated with
FIV-pPPRDvif Proviral DNA
Cat Virus inoculum
Viral antibody weeks postinoculation
2 4 8 12 16 27 43
073 FIV-Dvif —a — — — — — —
154 FIV-Dvif — — — — — — —
212 FIV-Dvif — — — — — — —
213 FIV-Dvif — — — — — — —
150 FIV-pPPR WT — — 103 103 103 Eb E
190 FIV-pPPR WT — — 102 102 102 E E
152 FIV-Petaluma — — 103 103 103 E E
191 FIV-Petaluma — — 103 103 103 E E
153 Unimmunized — — — — — — —
211 Unimmunized — — — — — — —
a Serum antibody titer to FIV p24 Gag expressed as the reciprocal of
the highest dilution positive for antibody. Sera with titers less than
1:100 are antibody negative.
b a
e
Cats infected with FIV-pPPR WT and FIV-Petaluma were euthanized
(E) 21 weeks pi.presence of anti-Env antibody in the pPPRDvif-inoculated
cats is indicative of expression of the vif-deleted provirus
post inoculation and suggests possible replication of the
virus.
FIV infection is associated with induction of FIV-spe-
cific effector and memory cytotoxic T-lymphocyte (CTL)
populations (Beatty et al., 1996; Flynn et al., 1996; Hosie
and Flynn, 1996; Song et al., 1992; Tellier et al., 1997). To
determine whether FIV-pPPRDvif proviral DNA inocula-
tion elicited a cellular immune response in cats, FIV-
specific lymphocytotoxicity in precursor CTLs was as-
sayed in PBMC harvested 21 weeks pi and stimulated in
vitro with fixed autologous stimulator cells infected with
recombinant vaccinia viruses expressing either FIV gag
or env gene product. Despite the inability to detect anti-
p24-Gag antibody responses, low but significant FIV
Gag- or Env-specific memory CTL activity was observed
in two of the four FIV-pPPRDvif-inoculated cats. One
FIV-pPPRDvif-inoculated cat (No. 213) and one FIV-Peta-
lumaPBMC virus-inoculated cat (No. 191) exhibited anti-FIV
ag CTL responses, whereas both uninfected control
ats were negative for anti-FIV Gag responses (Fig. 2). In
ddition, Env-specific CTL activity was detected in one
IV-pPPRDvif-inoculated cat (No. 073) and one FIV-Peta-
umaPBMC virus-inoculated cat (No. 191) but not in either
ninfected control cat. These results indicated that virus
eplication sufficient to induce CTL responses compara-
le to those observed in cats inoculated with FIV-Peta-
umaPBMC, occurred in at least two of the cats inoculated
ith FIV-pPPRDvif. However, CTL responses were mea-
urable in both cats inoculated with the more pathogenic
IV-PetalumaPBMC. It must be considered that additional
TL responses might have been found in the remaining
ats if earlier time points pi had been tested. The use of
lated with FIV-pPPRDvif Proviral DNA
A weeks postinoculation
Lymph node
proviral DNA
weeks
postinoculation
16 43 9 12
2 2 2 2
2 2 2 2
2 2 2 2
2 2 2 2
1 E 1 1
2 E 2 1
1 E 1 1
1 E 1 1
2 2 2 2
2 2 2 2ABLE 3
s Inocu
iral DN
8
2
2
2
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2vaccina virus construct expressing a heterologous FIV
nv (FIV-Petaluma Env), although of the same clade (A),
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71VACCINATION OF CATS WITH vif-DELETED FIV PROVIRAL DNAmay also have decreased the sensitivity of this CTL
assay for detection of FIV-pPPR Env-specific activity.
Challenge with infectious FIV
At 43 weeks pi, cats in the FIV-pPPRDvif-inoculated
group received a booster inoculation of 300 mg plasmid
FIV-pPPRDvif DNA. Adverse side effects were not ob-
served in any cat receiving a booster inoculation of
proviral DNA. Semi-quantitative virus isolation was per-
formed on PBMC isolated from the FIV-pPPRDvif-inocu-
lated cats on the day of boost (Table 2) and 6 weeks
postboost (Table 5). At 49 weeks after inoculation (6
weeks postboost), FIV-pPPRDvif-inoculated cats and two
SPF cats were challenged ip with 50 TCID50 of uncloned
FIV-PPR virus. Two additional SPF cats were inoculated
ip with uninfected tissue culture media. Cats were mon-
itored for clinical signs of acute FIV infection, viremia and
anti-FIV antibody and CTL activity for #47 weeks post-
challenge (pc). Three weeks pc, one FIV-pPPRDvif-inoc-
ulated cat (No. 073) was euthanized due to a progressive
nonregenerative anemia and neutropenia. Findings from
FIG. 1. Measurement of envelope-specific antibody responses. En
noculation (A), 12 weeks post proviral DNA inoculation (B), 4 weeks afte
LISA as described under Materials and Methods. Cats 073, 154, 212
challenge with biological FIV-PPR; Cats 150 and 190 were inoculated i
153 and 211 are unimmunized controls that were experimentally cha
control. Additional controls included high-titer serum from a long-term
control. The dotted horizontal line marks the O.D. value (0.250 AU) rep
IV-pPPRDvif-inoculated Cat 073, which was euthanized 3 weeks pc. Thistopathologic examination of lymphoid tissues har-
vested from this cat were not supportive of FIV-associ-ated disease and did not suggest an etiology for the
cause of the hematological abnormalities. Although pro-
viral DNA representative of challenge virus based on the
presence of wild-type vif sequences was detected in
both mesenteric lymph nodes and PBMC harvested from
the cat during post mortem examination, the cat was
virus isolation negative up until and including the time of
death. The remaining three cats inoculated with FIV-
pPPRDvif exhibited no clinical signs of acute FIV infec-
tion and remained clinically healthy throughout the 47
weeks following challenge. Significant decreases in
CD4:CD8 T cell ratios was not observed in either FIV-
pPPRDvif-immunized or unvaccinated control cats chal-
lenged with FIV-PPR virus when compared to age-
matched SPF control cats (data not shown). The lack of
CD4:CD8 T cell ratio alterations observed in the unvac-
cinated control cats is consistent with previous observa-
tions where decreased CD4 T cell concentrations were
associated only with a later stage of infection with the
FIV-PPR biological isolate (Sparger et al., 1994).
Both challenge control cats became viremic by PBMC
-specific serum antibody responses at 2 weeks post proviral DNA
nge (C), or 16 weeks after challenge (D) were measured by a FIV ConA
13 were inoculated im with FIV-pPPRDvif proviral DNA followed by ip
WT FIV-pPPR and subsequently became infected with FIV-pPPR; Cats
with biological FIV-PPR, and Cat 257 is a representative uninfected
taluma-infected cat as well as normal cat serum from an uninfected
tive of virus-specific reactivity. *, the previous data point occupied by
ults shown represent mean values for triplicate assays.velope
r challe
, and 2
m with
llenged
FIV/Pevirus isolation at 4 weeks pc (Table 5). Remarkably, virus
could not be isolated from any cat in the FIV-pPPRDvif-
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72 LOCKRIDGE ET AL.inoculated group throughout the 47 weeks following
challenge. SPF control cats also remained virus negative
throughout the study. Virus isolations performed on lym-
phocytes harvested from auricular lymph nodes sampled
at 12 weeks pc were also negative for all FIV-pPPRDvif-
inoculated cats and the SPF control cats, whereas virus
was isolated from lymph nodes harvested from both
challenge control cats (Table 5). Viral DNA was not de-
tected by PCR in PBMC collected at 2, 4, 12, 20, and 47
FIG. 2. Detection of FIV Gag- and Env-specific CTL following inocu-
lation. Virus-specific CTL responses were measured in restimulated
lymphocytes isolated from peripheral blood obtained at 21 weeks
following inoculation. Autologous skin fibroblasts infected with recom-
binant vaccinia virus expressing either FIV Gag (solid bars) or FIV Env
(striped bars) or with wild-type virus (dotted bars) were used in this
assay. The release of LDH into the culture supernatant was measured
after 4 h using a nonradioactive assay to assay-specific lysis. Results
shown are mean values for triplicate cultures at an effector to target
cell ratio of 25 to 1, with the exception of Cat 190 for which values
shown were measured at an E:T ratio of 10:1 due to an insufficient
number of effector cells for testing at multiple E:T ratios. In general,
specific lysis increased as E:T ratios increased from 3:1 up to 25:1. Due
to higher background LDH release observed with larger numbers of
effector cells, (PBMC), values for specific lysis at E:T ratios of 50:1 and
higher were not significant.
T
Detection of Virus in Immunized C
Cat
Virus
inoculum
PBMC virus isolatio
0 2 4 8 1
73 FIV-Dvif 2a 2 Eb E
154 FIV-Dvif 2 2 2 2 2
212 FIV-Dvif 2 2 2 2 2
213 FIV-Dvif 2 2 2 2 2
153 Unimmunized 2 2 104 104 1
211 Unimmunized 2 2 103 103 1
257 SPF Control 2 2 2 2 2
263 SPF Control 2 2 2 2 2irus could be isolated by day 42 in culture. A single concentration of lymph
b Cat was euthanized (E) 3 weeks pc and was virus isolation negative at tiweeks pc or in peripheral lymph nodes harvested at 12
weeks pc in the three surviving FIV-pPPRDvif-immunized
cats (Table 6). In contrast, viral DNA was amplified from
PBMC sampled from unimmunized control cats between
4 and 12 weeks pc and from auricular lymph nodes taken
at 12 weeks pc (Table 6). These observations are rele-
vant because previous vaccine studies have shown that
challenge virus may be detectable in lymphoid tissues,
although PBMC remain virus isolation negative following
challenge with FIV (Bishop et al., 1996; Hosie and Flynn,
996).
All cats were monitored for FIV seroconversion follow-
ng virus challenge by FIV p24-Gag antibody ELISA. Anti-
24-Gag antibody was detected in the sera of both chal-
enge control cats by 8 weeks pc, whereas anti-p24-Gag
ntibody was absent in the SPF control cats for the 47
eeks following challenge (Table 7). Importantly, anti-
24 antibody was never detected in any FIV-pPPRDvif-
noculated cats throughout the challenge phase of this
tudy, and these results were confirmed by commercial
LISA and Western blot. Taken together, the lack of
etectable viremia and absence of anti-p24 Gag anti-
ody in the FIV-pPPRDvif-inoculated cats indicate that
eplication of challenge virus was severely restricted in
hese cats and suggest that these cats were resistant to
nfection with WT homologous uncloned FIV-PPR.
Anti-Env antibody was detected in FIV-pPPRDvif-inoc-
lated cats at 4 and 12 weeks pc (Figs. 1C and 1D), and
ndpoint titers were comparable to those observed in
he unvaccinated challenge control cats (Nos. 153 and
11) (data not shown). Because sera were not available
rom FIV-pPPRDvif-inoculated cats on the day of chal-
enge (6 weeks postboost), a distinction between the
ntiviral responses derived from proviral DNA boost in-
culation and biological FIV-PPR challenge is not possi-
le. However, detection of anti-Env antibody following
allenged with Biological FIV-PPR
s postchallenge
Lymph node virus isolation
weeks postchallenge
16 20 24 47 12
E E E E E
2 2 2 2 2
2 2 2 2 2
2 2 2 2 2
105 103 105 104 1
103 105 105 105 1
2 2 2 2 2
2 2 2 2 2ABLE 5
ats Ch
n week
2
E
06
06
a PBMC or lymph node lymphocytes cultures negative for FIV p24 are shown as 2; numbers represent lowest concentration of cells from which
6node cells (10 ) was tested by virus isolation.
me of death.
02
2
1
2
ve at ti
73VACCINATION OF CATS WITH vif-DELETED FIV PROVIRAL DNAinitial proviral DNA inoculation and after proviral DNA
boost and challenge provides evidence for induction of
virus-specific humoral responses by inoculation with FIV-
pPPRDvif proviral DNA. These observations indicate that
this ConA ELISA previously adapted for detection and
characterization of HIV and SIV envelope-specific anti-
bodies (Cole et al., 1997; Robinson et al., 1990) will also
provide a sensitive assay for characterizing antibodies to
native FIV envelope proteins in future FIV vaccine stud-
ies.
Active cellular immune responses, including cytolytic
T cells have been shown to correlate with control of HIV
infection and hypothesized to be major components of
protective immunity induced by nef-deleted attenuated
SIV isolates (Borrow et al., 1994; Gallimore et al., 1996;
Gauduin et al., 1998; Mazzoli et al., 1997; Reimann et al.,
1994; Rosenberg et al., 1997; Schmitz et al., 1999; Yang et
al., 1997; Yasutomi et al., 1993). Env-specific effector CTL
in peripheral blood and Env-specific memory CTL in
lymphoid tissues were also reported to correlate with
protective immunity in cats immunized with a whole,
T
Detection of Proviral DNA in Immuniz
Cat
Virus
inoculum
PBMC proviral D
2 4
73 FIV-Dvif 2 Ea
154 FIV-Dvif 2 2
12 FIV-Dvif 2 2
13 FIV-Dvif 2 2
53 Unimmunized 2 1
11 Unimmunized 2 2
a Cat was euthanized (E) 3 weeks pc and was virus isolation negati
T
Detection of FIV p24 Antibody in Immun
Cat
Virus
inoculum 0a 2 4
073 FIV-Dvif ND 2b Ec
154 FIV-Dvif ND 2 2
212 FIV-Dvif ND 2 2
213 FIV-Dvif ND 2 2
153 Unimmunized ND 2 2
211 Unimmunized ND 2 102
257 SPF Control ND 2 2
263 SPF Control ND 2 2
a This time point represents challenge with 50 TCID50 of biological FIVSerum antibody titer to FIV p24 Gag is expressed as the reciprocal of the
c Cat was euthanized (E) 3 weeks pc and was viral antibody negative at timinactivated virus vaccine (Flynn et al., 1996; Hosie and
Flynn, 1996). To assess cellular immune responses as
possible correlates of protection in our study, FIV Gag-
and Env-specific memory CTL activity was measured for
in vitro stimulated PBMC isolated at 9, 14, and 17 weeks
following challenge. Both challenge control cats exhib-
ited elevated FIV Gag-specific activity 9 weeks following
challenge (Fig. 3A). This anti-Gag CTL activity returned to
baseline levels by 14 and 17 weeks pc. No significant
increase (10% specific lysis) in anti-Gag CTL activity was
observed for any of the FIV-pPPRDvif-inoculated cats
following challenge.
In addition to Gag-specific activity, a marked FIV
Env-specific CTL response was observed in challenge
control cats (Fig. 3B). Both challenge control cats dem-
onstrated heightened anti-Env CTL activity at 9 and 14
weeks but not at 17 weeks following challenge. In
contrast, only one FIV-pPPRDvif-inoculated cat (No.
213) exhibited significant anti-Env CTL activity at 9, 14,
and 17 weeks pc. This Env-specific response was
comparable to that observed for the challenge control
s Challenged with Biological FIV-PPR
eeks postchallenge
Lymph node proviral DNA
weeks postchallenge
20 47 12
E E E
2 2 2
2 2 2
2 2 2
1 1 1
1 1 1
me of death.
ats Challenged with Biological FIV-PPR
al antibody weeks postchallenge
8 12 16 20 24 47
E E E E E E
2 2 2 2 2 2
2 2 2 2 2 2
2 2 2 2 2 2
102 103 104 103 103 103
103 103 103 103 102 102
2 2 2 2 2 2
2 2 2 2 2 2
irus and is 5 weeks post booster inoculation with FIV-pPPRDvif proviralABLE 6
ed Cat
NA w
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E
2
2
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1
1ABLE 7
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Vir
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DNA.
b highest dilution positive for antibody.
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74 LOCKRIDGE ET AL.cats and was greatest at 9 weeks pc, then fell to a
small, but significant, level by 17 weeks. Neither of the
remaining two FIV-pPPRDvif-inoculated cats (Nos. 154
nd 212) exhibited a significant increase in anti-Env
TL activity at these time points. These observations
o not provide support for peripheral blood CTL activ-
ty as the predominant immune response responsible
or the protective immunity observed in the FIV-
PPRDvif-vaccinated cats. These findings are similar
o those of two different studies that revealed no
orrelation between antiviral CTL activity and induc-
ion of protective immune responses in cats vacci-
ated with a defective provirus encoding a deletion in
everse transcriptase (FIVDRT) and a DNA expression
construct encoding the feline gamma interferon gene
(Flynn et al., 2000; Hosie et al., 1998). However, anal-
ysis of memory CTL populations at earlier time points
after vaccination and boost and in lymphoid tissues of
FIV-pPPRDvif-vaccinated cats will be required to fur-
ther characterize CTL activity as a component of the
anti-FIV immune responses that allowed resistance to
viral challenge. Other cellular immune responses fa-
cilitating resistance to infection with challenge virus
FIG. 3. Detection of FIV Gag- and Env-specific CTL following chal-
lenge. The FIV-specific CTL activity was assayed in restimulated lym-
phocytes isolated from peripheral blood obtained following challenge
with 50 TCID50 of FIV-PPR virus. The FIV Gag-specific (A) and Env-
specific (B) CTL activities were measured at 9, 14, and 17 weeks
following challenge. Assay was performed as described in the legend
for Fig. 1. Results shown are mean values for triplicate cultures at an
effector to target cell ratio of 12.5 to 1, with the wild-type virus-infected
target cell values subtracted. No significant lysis was observed when
heterologous targets were used.may include CD8 T lymphocyte-derived antiviral fac-
tors, which have not yet been well characterized for
m
dFIV infection (Bucci et al., 1998; Jeng et al., 1996;
Shimojima et al., 1998).
Summary
We demonstrated that im injection of cats with FIV-
pPPRDvif proviral DNA did not produce an infection
detectable by virus isolation or induction of anti-FIV
Gag antibody for #49 weeks following inoculation.
However, cats inoculated with FIV-pPPRDvif proviral
DNA were resistant to challenge with homologous,
wild-type FIV. This observation contrasts with findings
of a different study where goats vaccinated with a vif
deletion mutant of caprine arthritis encephalitis virus
(CAEV) by proviral DNA inoculation were not protected
against WT CAEV challenge (Harmache et al., 1996)
and studies with SIV nef deletion mutants that suggest
that a detectable ongoing low-level replication of the
attenuated virus is needed for maintenance of protec-
tive immune responses (Wyand et al., 1996). However,
another study revealed protective immune responses
in African green monkeys inoculated with a nef dele-
ion mutant of SIVagm (SIVagm3nef) in the absence of
etectable replication of the immunizing virus (Beer et
l., 1997). Assessment for antibody and FIV-specific
TL responses did not reveal obvious immunological
echanisms for protection in these FIV-pPPRDvif-in-
culated cats. We speculate that FIV-pPPRDvif proviral
NA vaccination was successful at inducing protec-
ive immunity because of a combined effect of direct
xpression of viral antigens from the injected proviral
NA and a low-level of replication of attenuated virus
roduced by this DNA. Issues that need to be ad-
ressed are the time points following DNA inoculation
t which resistance to challenge virus was effectively
nduced and the need for a second proviral DNA in-
culation (boost). Assessment for virus/proviral DNA
n multiple lymphoid tissues harvested from FIV-
PPRDvif-inoculated cats at multiple time points will
lso be necessary to determine whether attenuated
irus is sequestered in such tissues. This study indi-
ates that a FIV vif deletion mutant, delivered by pro-
iral DNA injection, may provide an extremely attenu-
ted virus vaccine that is relatively safe from rever-
ion, yet capable of inducing protective immunity
ithout eliciting antibody responses that interfere with
iral diagnostic assays. Additional studies focusing on
he virus neutralizing activity and avidity of the low titer
nti-FIV Env antibody observed in the FIV-pPPRDvif-
accinated cats, as well as CTL activity and viral
uppressor factors, will be necessary to elucidate
echanisms by which inoculation of FIV-pPPRDvif in-
uces resistance to infection with WT homologous FIV.
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75VACCINATION OF CATS WITH vif-DELETED FIV PROVIRAL DNAMATERIALS AND METHODS
Construction of mutants
The infectious molecular clone WT FIV-pPPR, derived
from the FIV-PPR isolate and kindly provided by J. E.
Elder, served as the parental construct (Phillips et al.,
1990). Vif-deletion mutant FIV-pPPRDvif was created by
introducing a 375-bp (bp 5330–5704) deletion within the
vif gene of the WT FIV-pPPR clone, as previously de-
scribed (Lockridge et al., 1999). Plasmid DNA stocks
were prepared by centrifugation to equilibrium twice in
cesium chloride–ethidium bromide gradients (Sambrook
et al., 1989) and were not assayed for endotoxin concen-
tration. Plasmid DNA stocks used for the boost inocula-
tion at 43 weeks pi were further purified using Endofree
Columns (Qiagen Corp.) and endotoxin was undetect-
able in these plasmid DNA preparation when assayed by
a commercial kit (E-Toxate, Sigma Chemical Co.).
Virus stocks
The FIV-PetalumaPBMC virus stock was generated by
hort-term (,2 weeks) passage of the biological FIV
etaluma isolate in feline PBMC cultured in complete
PMI media supplemented with recombinant human in-
erleukin-2 (IL-2; 100 U/ml), 10% heat inactivated fetal
ovine serum (FBS), L-glutamine, and penicillin–strepto-
ycin. The biological FIV-PPR virus stock used for chal-
enge was derived from a virus preparation chronically
assaged on feline PBMC.
nimals and inoculations
Twelve juvenile, SPF cats, aged 4–5 months, were
btained from the SPF cat colony of Dr. J. G. Morris and
r. Q. R. Rogers (University of California, Davis) and
oused in pathogen-free quarters of Animal Resources
ervices (University of California, Davis). Cats were in-
culated by im injection with 600 mg of either FIV-
PPRDvif plasmid DNA (n 5 4) or WT FIV-pPPR plasmid
NA (n 5 2) or were inoculated ip with 103 TCID50 of
biological FIV-PetalumaPBMC virus stock (n 5 2) (Table 1).
Two negative control cats were inoculated ip with unin-
fected tissue culture media only. Plasmid DNA was re-
suspended in 1 ml of sterile physiological saline for
inoculation by hypodermic syringe (22 gauge) in the rear
limb quadriceps muscle. Animals were assessed daily
by physical examination and monitored for clinical signs.
Blood samples were obtained every two to four weeks
for hematological, virological, and immunological as-
says. Popliteal lymph nodes were sampled at 9 and 12
weeks postinoculation. Cats in the WT FIV-pPPR- and
FIV-PetalumaPBMC-inoculated groups were sacrificed at
1 weeks pi. At 43 weeks pi, all cats in the FIV-pPPRDvif-
noculated group received a booster inoculation im with
00 mg FIV-pPPRDvif plasmid DNA.hallenge
At 49 weeks pi (6 weeks postboost), FIV-pPPRDvif-
noculated cats and two SPF cats were challenged ip
ith 50 TCID50 of an uncloned, biological FIV-pPPR virus
stock. Two negative control cats were inoculated ip with
uninfected tissue culture media only. At 3 weeks pc (52
weeks pi), one cat from the FIV-pPPRDvif group was
euthanized due to a progressive nonregenerative ane-
mia. However, viremia was not detected in this cat at the
time of death. Blood samples were collected at similar
time points as described for DNA inoculation and auric-
ular lymph nodes were sampled at 12 weeks post chal-
lenge.
Virus isolation
Semi-quantitative virus isolations were performed on
PBMC isolated from peripheral blood by density gradient
centrifugation in Ficoll/Hypaque (Histopaque; Sigma).
Tenfold serial dilutions of 106 PBMC were cocultured
ith SPF feline PBMC in 24-well plates. Culture super-
atants were collected every 3–5 days and virus produc-
ion was measured by p24 antigen-capture ELISA (Dan-
ekar et al., 1992) for #32 days as previously described
Sparger et al., 1997). Single-cell suspensions of mono-
uclear cells were prepared by gentle manual homoge-
ization of auricular lymph node biopsies. For lymph
ode-derived mononuclear cells, 106 cells were cultured
ndiluted in 24-well plates for 28 days and assayed for
irus by p24 antigen ELISA as described above.
ematology and lymphocyte subset analysis
Complete blood cell counts and differential leukocyte
ounts were performed on peripheral blood samples
sing standard methods as previously described (Bar-
ough et al., 1991). Enumeration of CD4 and CD8 periph-
eral blood lymphocyte subsets and CD4:CD8 ratios were
performed by flow cytometric analysis also as previously
described (Barlough et al., 1991).
Anti-FIV Gag antibody detection
Circulating antibodies to FIV p24-Gag in sera following
inoculation and challenge were detected by ELISA with
recombinant p24 as the solid-phase antigen as previ-
ously described (George et al., 1993). A commercially
available anti-FIV antibody ELISA detection kit (IDEXX),
as well as Western blot, were used to confirm results
from the recombinant p24 ELISA.
Detection of proviral DNA by PCR
Genomic DNA was extracted from PBMC and periph-
eral lymph nodes using a commercial kit (QIAamp Tissue
Kit, Qiagen Corp.) and was assayed for FIV proviral DNA
by nested PCR using conditions previously described
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76 LOCKRIDGE ET AL.(Dean et al., 1999). Round-one primers used were as
follows: GAG 1: GGGAATGGACAGGGGCGAGAT (for-
ward) and GAG 2: TTGCTGCACTTGATTCACTGG (re-
verse). Second-round primers were GAG3: TTGAC-
CCAAAAATGGTGTCCA (forward) and GAG5: GCTGGTG-
CAAATCTTGCTTC (reverse) and yielded a 312-bp
product. Each sample was tested three times or more by
PCR amplification before a final result was recorded.
Nested PCR using these Gag primers detected ,20
roviral copies per microgram of genomic DNA.
etection of FIV Env antibody by ELISA
Serum samples from inoculated cats were analyzed
or their reactivity to native viral envelope proteins in a
onA ELISA. This assay maximizes the maintenance of
rotein structure and has been adapted from assays
reviously described for HIV-1 (Robinson et al., 1990) and
odified for SIV (Cole et al., 1997). Briefly Immulon 2HB
lates (Dynatech Laboratories) were incubated with 5.0
mg ConA (Vector Laboratories) per well in 100 ml of
hosphate-buffered saline (PBS) for 1 h at room temper-
ture and then washed two times with PBS/0.05%
ween-20. ConA plates were then used to adsorb enve-
ope glycoproteins from Triton X-100-disrupted, gradient
urified preparations of biological FIV-PPR (1 mg of total
protein, as determined by Biorad DC Protein assay, per
50 ml in each well) for 2 h at room temperature. ConA-
adsorbed wells were next washed five times with PBS/
0.05% Tween-20 and blocked with 100 ml per well of
LOTTO (5% nonfat dry milk in PBS/0.05% Tween-20) per
ell overnight at 4°C. After blocking solution was re-
oved, 50 ml of serial dilutions (1:50–51,200 in blotto) of
each serum sample were added to each well and incu-
bated for 1 h at room temperature. Sample wells were
again washed five times with PBS/0.05% Tween-20 be-
fore incubating 50 ml of peroxidase-conjugated anti-cat
gG (Kirkgaard and Perry Laboratories) per well for a 1-h
ncubation at room temperature. Wells were once again
ashed five times with PBS/0.05% Tween-20, and 200 ml
f TM-Blue (Intergen) substrate was added and left for 20
in while shaking at room temperature. Color develop-
ent was determined by the addition of 50 ml of 1 N
ulfuric acid per well. Antibody reactivity to ConA-ad-
orbed glycoprotein substrates was then determined by
easuring optical density (O.D.) at 450 nm, using an
utomated plate reader (Dynatech).
ytotoxic T-lymphocyte assay
Virus-specific CTL activity was measured in PBMC of
accinated and control cats at various time points after
noculation and challenge, using a method previously
escribed (Beatty et al., 1996), with the following modifi-
ations. Target cells were autologous skin fibroblasts
ollected by skin biopsy prior to inoculation and stored athird passage at 270°C. Stimulator cells (Flynn et al.,
1996) were prepared from autologous PBMC collected
both prior to and following inoculation and cultured in
complete RPMI media supplemented with 7.5 mg/ml
ConA (Sigma), IL-2 (100 U/ml), 10% heat inactivated FBS,
L-glutamine, and penicillin–streptomycin, for 48 h at
7°C. Lymphoblasts were infected with 10 PFU/cell of
ecombinant vaccinia virus expressing either FIV-Gag
vFIV-GL14-gag, provided by J. Flynn, Glasgow, Scotland)
r FIV-Env (vFIV-PET-env, provided by E. B. Stephens,
ainesville, FL) proteins in complete RPMI for 1 h. Cells
ere washed and resuspended in complete RPMI with
% FBS for 3 h at 37°C to allow optimal expression of the
IV proteins, then fixed overnight in 0.1% paraformalde-
yde in PBS at 4°C. Cells were washed before storage at
3 106 cells/ml in PBS at 4°C. PBMC serving as effector
ells were restimulated in vitro by addition of fixed anti-
en-presenting vFIV/GL14-gag or vFIV/PET-env stimula-
or cells at a stimulator to responder ratio of 1:10 to 1:20.
ffectors were cultured for 5–7 days with stimulator cells
n complete RPMI media, then an additional 5–7 days in
omplete RPMI media containing 200 U/ml IL-2.
The day before the CTL assay, 1 3 104 target cells per
well in DMEM/L-15 media supplemented with 10% FBS
were seeded into round-bottomed 96-well microtiter plates
to form confluent monolayers during an overnight, 37°C
incubation. On the morning of the assay, target cells were
washed and then infected with 5 PFU/cell of either wild-
type vaccinia virus (vWT), vFIV-gag, or vFIV-env in media
composed of equal parts minimum essential medium
(MEM) and Leibovitz’ L-15, supplemented with L-glutamine
nd penicillin-streptomycin. Cells were incubated with virus
or 1 h, washed once, then incubated in DMEM/L-15 media
upplemented with 2% FBS at 37°C for an additional 2 h.
ffectors in complete RPMI media without phenol red and
upplemented with 5% FBS were added to washed target
ells at various effector:target ratios in a final volume of 200
ml and allowed to incubate for 4 h at 37°C. Cytotoxicity was
measured by release of lactate dehydrogenase (LDH), a
stable cytosolic enzyme that is released upon cell lysis,
using the CytoTox 96 kit (Promega Biotech), as per manu-
facturer’s instructions.
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